Nesiritide

Overview

Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is a 32 amino acid recombinant human B-type natriuretic peptide.

Indication

适用于急性代偿性心力衰竭、慢性失代偿性心力衰竭、心肌梗死、心脏导管手术等。由于静脉使用起效快，更适用于急性心力衰竭。

Associated Conditions

Acute Decompensated Heart Failure (ADHF)

Clinical Trials

View More Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.	2005/12/26	NCT00270361	Phase 3	Completed	Scios, Inc.
A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.	2005/12/26	NCT00270374	Phase 3	Completed	Scios, Inc.
A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure	2005/12/26	NCT00270400	Phase 3	Completed	Scios, Inc.
BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling	2005/11/11	NCT00252213	Phase 1	Terminated	Mayo Clinic
Nesiritide and Vo2 Max in Heart Failure Patients	2005/10/17	NCT00240084	Phase 2	Completed	University of Rochester
Catheterization Laboratory Study: Acute Responses in Diastolic Heart Failure	2005/09/20	NCT00204945	Not Applicable	Completed	University of Wisconsin, Madison
Natrecor for Pulmonary Hypertension in Lung Transplants	2005/09/20	NCT00205426	Phase 4	Completed	University of Wisconsin, Madison
Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure	2005/09/15	NCT00170183	Phase 3	Completed	Mayo Clinic
Effects of Nesiritide in Pediatric Patients With Heart Failure	2005/09/14	NCT00166010	Not Applicable	Withdrawn	Emory University
Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction	2005/07/14	NCT00119691	Phase 2	Completed	Brigham and Women's Hospital

FDA Drug Approvals

View More FDA Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

View More EMA Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access